NCT04764474 - A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2021

Primary Completion Date

January 15, 2025

Study Completion Date

January 15, 2025

Conditions

Isocitrate Dehydrogenase Gene Mutation

Interventions

DRUG

HMPL-306

Administered orally QD in a 28-day continuous dosing treatment cycle

Trial Locations (15)

START Madrid - Hospital Universitario Fundacion Jimenez Diaz, Madrid

Hospital Universitario 12 de Octubre, Madrid

Winship Cancer Institute - Emory University, Atlanta

Clinica Universidad de Navarra, Pamplona

The Ohio State University Comprehensive Cancer Center, Columbus

Hospital Clinico Universitario de Valencia, Valencia

Hospital Universitario La Fe, Valencia

Froedtert-Medical College of WI, Milwaukee

The University of Texas MD Anderson Cancer Center, Houston

University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Orange

University of Massachusetts Medical School, Worcester

Rutgers Cancer Institute of New Jersey, New Brunswick

Hospital Universitario Vall d'Hebron, Barcelona

Institut Catala d'Oncologia de l'Hospitalet de Llobregat - Hospital Duran i Reynals, Barcelona

Hospital Universitario de Salamanca, Salamanca